Alwaysraise
Advisory and investment firm providing fundraising, mergers & acquisitions, and corporate development advisory services focused on medical devices, pharmaceuticals and digital health. Offers a structured three‑stage fundraising methodology, transaction execution support, investor outreach and licensing/partnership advisory with experience in cross‑border life‑science transactions and integration of clinical and regulatory milestones into transaction planning.
Industries
Nr. of Employees
small (1-50)
Alwaysraise
San Francisco, California, United States, North America
Services
A three‑stage fundraising advisory process covering readiness assessment, investor outreach and deal closing to support capital raises for medical device, pharmaceutical and digital health companies.
End‑to‑end M&A advisory including deal strategy, partner identification, negotiation support and transaction closing coordination.
Advisory on licensing, partnering, license‑in/license‑out strategies and strategic business model transformation for biopharma and medtech firms.
A three‑stage fundraising advisory process covering readiness assessment, investor outreach and deal closing to support capital raises for medical device, pharmaceutical and digital health companies.
End‑to‑end M&A advisory including deal strategy, partner identification, negotiation support and transaction closing coordination.
Advisory on licensing, partnering, license‑in/license‑out strategies and strategic business model transformation for biopharma and medtech firms.
Expertise Areas
- Private placements and venture fundraising
- Mergers & acquisitions advisory for life sciences
- Corporate development and licensing for biopharma and medtech
- Regulatory and path‑to‑market strategy
Key Technologies
- Digital health platforms
- Medical device technologies
- Therapeutic drug development pipelines
- Remote patient monitoring and implantable remote care technologies
News & Updates
Article discussing stereotactic radiosurgery and its role in treating brain tumors and the projected increase in cancer incidence.
Advised Oncodisc Inc. in its acquisition by a PAVmed subsidiary to advance development of intelligent implantable remote care technology.
Coverage of Immix Biopharma filing for and completing a NASDAQ initial public offering to raise capital for tissue‑specific oncology therapies (Phase 1b/2a).
Article discussing stereotactic radiosurgery and its role in treating brain tumors and the projected increase in cancer incidence.
Advised Oncodisc Inc. in its acquisition by a PAVmed subsidiary to advance development of intelligent implantable remote care technology.
Coverage of Immix Biopharma filing for and completing a NASDAQ initial public offering to raise capital for tissue‑specific oncology therapies (Phase 1b/2a).